Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Determination of the Inhibitory Activity of the Compounds on Human P2X3 and P2X2/3 Receptors from US Patent US11919918: "P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof"
Assay data:106 Active, 101 Activity ≤ 1 µM, 106 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Evaluation of In Vitro Biological Activity from US Patent US20240034729: "HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF"
Assay data:163 Active, 4 Activity ≤ 1 nM, 193 Activity ≤ 1 µM, 194 Tested
Selectivity interaction (Lead profiling screen (Eurofins, GPCRs, ion channels, kinases and transporters)) EUB0000309b P2RX3
Assay data:1 Active, 1 Tested
SummaryCompounds, ActiveRelated BioAssays by Target
Inhibition of P2X3 receptor (unknown origin)
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Antagonist activity at human P2X2R/P2X3R expressing CHO cells assessed as reduction in intracellular Ca2+ influx pretreated with Fluo-4 for 1 hr followed by compound addition and further incubated for 30 mins in presence of ATP by multimode plate reader analysis
Assay data:3 Tested
Antagonist activity at human P2X3R expressing CHO cells assessed as reduction in intracellular Ca2+ influx pretreated with Fluo-4 for 1 hr followed by compound addition and further incubated for 30 mins in presence of ATP by multimode plate reader analysis
Agonist activity at human P2X2R/P2X3R expressing CHO cells assessed as reduction in intracellular Ca2+ influx pretreated with Fluo-4 for 1 hr followed by compound addition and further incubated for 30 mins in presence of ATP by multimode plate reader analysis
Assay data:10 Active, 7 Activity ≤ 1 µM, 16 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Agonist activity at human P2X3R expressing CHO cells assessed as reduction in intracellular Ca2+ influx pretreated with Fluo-4 for 1 hr followed by compound addition and further incubated for 30 mins in presence of ATP by multimode plate reader analysis
Assay data:6 Active, 3 Activity ≤ 1 µM, 16 Tested
Antagonist activity at human P2X3R expressed in HEK293 cells assessed as reduction in alphabeta-MeATP-induced intracellular Ca2+ influx pretreated with compound followed by alphabeta-MeATP addition and measured by Fluo-4 dye fluorescence analysis
Assay data:12 Active, 5 Activity ≤ 1 µM, 21 Tested
Non-competitive antagonist activity at human P22X3 receptor assessed as right shift in alphabetameATP-induced calcium influx by measuring maximum efficacy of agonist at 200 nM relative to control
Assay data:2 Tested
Antagonist activity at human P2X2R/P2X3R by cell based assay
Assay data:3 Active, 3 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Antagonist activity at human P2X3 receptor at 2 uM by cell based assay relative to control
Assay data:8 Tested
Antagonist activity at human P2X3 receptor by cell based assay
Assay data:11 Active, 8 Activity ≤ 1 µM, 18 Tested
Antagonist activity at human P2X3R transfected in CHO-K1 cells at 30 uM preincubated for 30 mins followed by alpha,beta-meATP addition by fluorescence based assay relative to control
Assay data:20 Tested
Antagonist activity at human P2X3R transfected in CHO-K1 cells preincubated for 30 mins followed by alpha,beta-meATP addition by fluorescence based assay
Assay data:1 Active, 1 Activity ≤ 1 µM, 3 Tested
Antagonist activity at human P2X2/3R transfected in CHO-K1 cells at 30 uM preincubated for 30 mins followed by alpha,beta-meATP addition by fluorescence based assay relative to control
Antagonist activity at human P2X2/3R transfected in CHO-K1 cells preincubated for 30 mins followed by alpha,beta-meATP addition by fluorescence based assay
Antagonist activity at human P2X3R expressed in HEK293 cells assessed as reduction in intracellular Ca2+ influx at 10 uM pretreated with Fluo-4 for 1 hr followed by compound addition and further incubated for 30 mins in presence of ATP by multimode plate reader analysis relative to control
Assay data:4 Tested
Antagonist activity at P2X3 receptor (unknown origin)
Assay data:38 Active, 37 Activity ≤ 1 µM, 38 Tested
Biological Assay from US Patent US10472354: "1,3-thiazol-2-yl substituted benzamides"
Assay data:389 Active, 1 Activity ≤ 1 nM, 385 Activity ≤ 1 µM, 389 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on